BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 15057050)

  • 1. Sentinel lymph node dissection in stage I/II melanoma patients: surgical management and clinical follow-up study.
    Macripò G; Quaglino P; Caliendo V; Ronco AM; Soltani S; Giacone E; Pau S; Fierro MT; Bernengo MG
    Melanoma Res; 2004 Apr; 14(2):S9-12. PubMed ID: 15057050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sentinel lymph node biopsy in melanoma patients with clinically negative regional lymph nodes--one institution's experience.
    Nowecki ZI; Rutkowski P; Nasierowska-Guttmejer A; Ruka W
    Melanoma Res; 2003 Feb; 13(1):35-43. PubMed ID: 12569283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcome of stage I/II melanoma patients after selective sentinel lymph node dissection: long-term follow-up results.
    Vuylsteke RJ; van Leeuwen PA; Statius Muller MG; Gietema HA; Kragt DR; Meijer S
    J Clin Oncol; 2003 Mar; 21(6):1057-65. PubMed ID: 12637471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The long-term results and prognostic significance of cutaneous melanoma surgery using sentinel node biopsy with triple technique.
    Rutkowski P; Szydłowski K; Nowecki ZI; Sałamacha M; Goryń T; Mitręga-Korab B; Pieńkowski A; Dziewirski W; Zdzienicki M
    World J Surg Oncol; 2015 Oct; 13():299. PubMed ID: 26462471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morbidity and outcome after sentinel lymph node dissection in patients with early-stage malignant cutaneous melanoma.
    Blumenthal R; Banic A; Brand CU; Ris HB; Lardinois D
    Swiss Surg; 2002; 8(5):209-14. PubMed ID: 12422766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy.
    McMasters KM; Egger ME; Edwards MJ; Ross MI; Reintgen DS; Noyes RD; Martin RC; Goydos JS; Beitsch PD; Urist MM; Ariyan S; Sussman JJ; Davidson BS; Gershenwald JE; Hagendoorn LJ; Stromberg AJ; Scoggins CR
    J Clin Oncol; 2016 Apr; 34(10):1079-86. PubMed ID: 26858331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The analysis of the outcomes and factors related to iliac-obturator involvement in cutaneous melanoma patients after lymph node dissection due to positive sentinel lymph node biopsy or clinically detected inguinal metastases.
    Zdzienicki M; Rutkowski P; Nowecki ZI; van Akkooi AC; Michej W; Dziewirski W; Świtaj T; Pieńkowski A; Sałamacha M; Bylina E; Eggermont AM
    Eur J Surg Oncol; 2013 Mar; 39(3):304-10. PubMed ID: 23298828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-institution experience in the management of patients with clinical stage I and II cutaneous melanoma: results of sentinel lymph node biopsy in 240 cases.
    Rex J; Paradelo C; Mangas C; Hilari JM; Fernández-Figueras MT; Fraile M; Alastrué A; Ferrándiz C
    Dermatol Surg; 2005 Nov; 31(11 Pt 1):1385-93. PubMed ID: 16416605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?
    Mays MP; Martin RC; Burton A; Ginter B; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; McMasters KM; Scoggins CR
    Cancer; 2010 Mar; 116(6):1535-44. PubMed ID: 20108306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
    Eggermont AM
    Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymph node status and survival in cutaneous malignant melanoma--sentinel lymph node biopsy impact.
    Rutkowski P; Nowecki ZI; Nasierowska-Guttmejer A; Ruka W
    Eur J Surg Oncol; 2003 Sep; 29(7):611-8. PubMed ID: 12943629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sentinel lymph node biopsy in patients with primary cutaneous melanoma: study of 455 cases.
    Landi G; Polverelli M; Moscatelli G; Morelli R; Landi C; Fiscelli O; Erbazzi A
    J Eur Acad Dermatol Venereol; 2000 Jan; 14(1):35-45. PubMed ID: 10877250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
    Nowecki ZI; Rutkowski P; Michej W
    Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic implications of anatomic location of primary cutaneous melanoma of 1 mm or thicker.
    Callender GG; Egger ME; Burton AL; Scoggins CR; Ross MI; Stromberg AJ; Hagendoorn L; Martin RC; McMasters KM
    Am J Surg; 2011 Dec; 202(6):659-64; discussion 664-5. PubMed ID: 22137134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The benefit of a sentinel lymph node biopsy and adjuvant therapy in thick (>4 mm) melanoma: multicenter, retrospective study of 291 Japanese patients.
    Fujisawa Y; Otsuka F;
    Melanoma Res; 2012 Oct; 22(5):362-7. PubMed ID: 22713797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor mitotic rate added to the equation: melanoma prognostic factors changed? : a single-institution database study on the prognostic value of tumor mitotic rate for sentinel lymph node status and survival of cutaneous melanoma patients.
    Speijers MJ; Bastiaannet E; Sloot S; Suurmeijer AJ; Hoekstra HJ
    Ann Surg Oncol; 2015 Sep; 22(9):2978-87. PubMed ID: 25605514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma.
    Nowecki ZI; Rutkowski P; Nasierowska-Guttmejer A; Ruka W
    Ann Surg Oncol; 2006 Dec; 13(12):1655-63. PubMed ID: 17016755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.
    Mandalà M; Imberti GL; Piazzalunga D; Belfiglio M; Labianca R; Barberis M; Marchesi L; Poletti P; Bonomi L; Novellino L; Di Biagio K; Milesi A; Guerra U; Tondini C
    Eur J Cancer; 2009 Sep; 45(14):2537-45. PubMed ID: 19553103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sentinel lymph node biopsy in acral melanoma: A Korean single-center experience with 107 patients (2006-2018).
    Sohng C; Sim HB; Kim JY; Lim Y; Han MH; Lee H; Ahn BC; Huh S; Lee SJ
    Asia Pac J Clin Oncol; 2021 Feb; 17(1):115-122. PubMed ID: 33079454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic significance of non-sentinel lymph node metastasis in cutaneous and acral melanoma patients-A multicenter retrospective study.
    Sun W; Xu Y; Yang J; Liao Z; Li T; Huang K; Patel P; Yan W; Chen Y
    Cancer Commun (Lond); 2020 Nov; 40(11):586-597. PubMed ID: 33025763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.